Coloplast stock trades steadily as growth and margins support valuation
Published on 07/19/2026 at 17:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Coloplast stock represents exposure to a Danish medtech group with a long record of profitable growth. The company (ISIN DK0060448595) focuses on ostomy care, continence care and related medical products, and its latest reported financial year shows that revenue expansion and margin discipline continue to underpin the equity story.
Revenue grows 5 percent
According to Coloplast's annual report for the financial year 2023/24, the company generated revenue of around DKK 23.0 billion in the period, reflecting an organic growth rate in the mid-single-digit range. The group has for several years guided and delivered organic growth in a corridor around 5 percent, and the reported performance in the latest year remained close to that pace. The ability to maintain mid-single-digit growth in a mature ostomy and continence care market is one of the reasons many investors follow Coloplast stock as a defensive healthcare holding.
In the same annual period, Coloplast reported an earnings before interest and taxes (EBIT) figure of roughly DKK 6.0 billion. This translates into an EBIT margin in the high-twenties percent range, a level that stands visibly above many diversified medtech peers. Compared with the previous financial year, EBIT increased by several hundred million Danish kroner, and the EBIT margin widened by around one percentage point, indicating that cost discipline and mix effects supported profitability even as the company invested in geographic expansion and product innovation.
Net income attributable to shareholders in the latest full financial year was in the region of DKK 4.5 billion. This result was higher than in the prior year by several hundred million kroner, reflecting the combined impact of revenue growth and margin improvement. The corresponding earnings per share (EPS) rose by a high-single-digit percentage compared with the previous year, underlining that Coloplast stock is backed by a steadily rising profit stream.
Margins near 28 percent
For many investors, the most striking metric in Coloplast's financial profile is the operating margin. In the recent annual report, the company disclosed an EBIT margin close to 26–28 percent, depending on the exact definition used, which is meaningfully higher than the mid-teens to low-twenties percent ranges often seen among broader medtech companies. This margin has improved versus the previous year by about one percentage point, and the sustained level over several reporting periods suggests structural efficiency in manufacturing and distribution as well as a focus on higher-value products.
The gross margin in Coloplast's latest financial year also remained robust, in the ballpark of 70 percent. Historically, the group has reported gross margins around that level, and the latest figure was only slightly changed versus the prior year, indicating that input-cost and currency factors did not materially erode the profitability of the product portfolio. For investors, this stability at the gross-margin level is an important support for the resilience of EBIT and net profit when the company invests in sales capacity and digital solutions.
Cash generation complements the margin story. In the most recent full year, Coloplast reported free cash flow of roughly DKK 3.0 billion, which was higher than in the previous year by several hundred million kroner. This improvement reflected both higher operating profit and disciplined capital expenditure, and it gives the company room to continue its historical pattern of paying dividends and occasionally adjusting its capital structure.
Dividend and capital returns
Coloplast has a long record of distributing a significant portion of its earnings to shareholders via dividends. In the latest financial year, the board proposed a total dividend in the region of DKK 22–24 per share, which marked an increase compared with the previous year's payout. The year-on-year increase was in the mid-single-digit percentage range, broadly aligned with EPS growth, and underlines the company's policy of gradually raising the dividend as profits expand.
On top of the ordinary dividend, Coloplast has in earlier years occasionally used share buybacks to return capital when leverage and investment needs allowed. In the latest financial year, the company maintained a relatively moderate net debt position, with net interest-bearing debt corresponding to roughly one times EBITDA, leaving balance sheet flexibility. For Coloplast stock, this combination of high margins, growing earnings and a disciplined capital-return policy shapes the total shareholder return profile.
The company also continues to invest in research and development and in marketing to support long-term growth. In the recent annual period, R&D and other innovation-related spending amounted to several hundred million kroner, representing a low- to mid-single-digit percentage of revenue. This spending is directed at new product features, digital tools for patients and clinicians, and incremental improvements to existing portfolios in ostomy and continence care as well as wound and skin care.
Guidance and growth ambitions
In its latest guidance communication for the current financial year, Coloplast outlined expectations for organic revenue growth around the mid-single-digit level. The company indicated that it aims to sustain organic growth close to 7 percent over the medium term, supported by demographic trends, increased healthcare access and product innovation. At the same time, management targets an EBIT margin in the high-twenties percent range, implying continued focus on efficiency as growth investments are made.
Compared with the prior-year realized organic growth of around 5 percent, the medium-term ambition of approximately 7 percent would represent a step-up if achieved. For Coloplast stock, the key question is whether new products and geographic expansion can lift the growth rate while keeping margins near the targeted level. The guidance also assumes that currency effects and regulatory developments remain broadly manageable.
Coloplast's geographic mix is relatively diversified. In the latest annual report, the company indicated that Europe still generates the largest portion of revenue, but emerging markets and North America have been growing faster. Revenue in emerging markets increased at a double-digit percentage rate year on year, from a smaller base, and contributed to the group's overall organic growth. Such regional dynamics are relevant for investors assessing the long-term demand profile.
Product segments and mix
Coloplast organizes its activities into several major segments, including Ostomy Care, Continence Care, and Wound and Skin Care. In the latest full year, Ostomy Care remained the largest segment by revenue, generating more than DKK 10 billion in sales. Continence Care contributed roughly DKK 8 billion, while Wound and Skin Care and other smaller activities made up the remainder. Each segment reported organic growth, with Continence Care and Wound and Skin Care typically growing faster than the more mature Ostomy Care segment.
Segment margins differ, but Ostomy Care and Continence Care both provide strong profitability. Ostomy Care leveraged its scale and established product ranges to maintain high margins, while Continence Care benefited from increased penetration of advanced devices. Wound and Skin Care, though smaller, showed an improvement in margin thanks to efforts to optimize product portfolios and routes to market.
The mix between chronic care products and more discretionary items also matters. Coloplast's focus on chronic care, which includes products for long-term conditions such as ostomies and incontinence, contributes to revenue stability even when macroeconomic conditions are less favorable. This stability is one reason Coloplast stock is often viewed as a defensive healthcare exposure.
Coloplast SenSura Mio in ostomy care
One of Coloplast's representative product lines in ostomy care is the SenSura Mio series of ostomy bags and supporting devices. SenSura Mio products are designed to provide enhanced fit, discretion and comfort for people living with a stoma, and they form a key part of the company's offerings in that segment. While Coloplast does not break out revenue for SenSura Mio alone, ostomy products overall contribute more than DKK 10 billion in annual sales, and ongoing innovation in ranges such as SenSura Mio is central to sustaining that contribution.
The company continues to launch incremental updates and variants within the SenSura Mio line, focusing on features like adaptive fit and improved materials. These innovations aim to support patient quality of life and maintain competitive differentiation, which in turn supports pricing and margin resilience.
Coloplast stock and market context
Coloplast shares trade on Nasdaq Copenhagen under the symbol COLO B. The market capitalization in recent months has been around DKK 200–250 billion, reflecting investor expectations of continued profitable growth and stable dividends. The share price has historically traded at a premium valuation multiple compared with broader European equity indices, in part because of the company's defensive profile and strong margins.
As of a recent trading day in mid-2026, the Coloplast share price on Nasdaq Copenhagen was around DKK 950–1,000, placing the stock not far from the upper half of its 52-week trading range. Over the past 12 months, Coloplast stock has moved between roughly DKK 800 and DKK 1,050, and the current level sits closer to the higher end of that range. This pattern suggests that the market continues to ascribe a high valuation to the company despite cyclical concerns in broader equity markets.
For investors, the core elements behind Coloplast stock are clear: mid-single-digit organic growth, high-twenties percent EBIT margins, robust cash generation and a progressive dividend. The main sensitivities include regulatory developments in healthcare funding, competitive dynamics in chronic care products and currency movements, particularly for revenues outside Denmark and the euro area. Within that framework, the company aims to deliver on its guidance and maintain the balance between growth investment and shareholder returns.
Fact box: Coloplast basics
Coloplast A/S is a Danish medical technology company headquartered in Humlebæk, Denmark. Its shares are listed on Nasdaq Copenhagen under the ticker COLO B, and the ISIN is DK0060448595. The company forms part of the OMX Copenhagen 25 index, reflecting its status as one of the larger and more liquid Danish equities. Coloplast operates globally, with products sold in numerous countries through direct sales organizations and partners.
The company focuses on chronic care markets, primarily ostomy and continence care, and complements these with wound and skin care solutions. Revenue in the latest annual period was around DKK 23.0 billion, EBIT roughly DKK 6.0 billion, and net income about DKK 4.5 billion. The balance sheet carries moderate net debt, and free cash flow stands near DKK 3.0 billion per year, supporting dividends and selective investments. For investors considering exposure to healthcare with a defensive profile, these metrics frame the fundamental backdrop for Coloplast stock.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
